White House drops proposal to eliminate drug rebates. Health stocks soar

cnbc | July 11, 2019

The Trump administration has withdrawn its proposal to eliminate rebates from government drug plans, a key component of the president’s blueprint to lower prescription drug prices, a White House spokesman confirmed.

Spotlight

What matters most when building and sustaining a healthcare organization? What are the precise levers to pull to promote physician well-being, financial success, and better outcomes at lower cost? To answer these questions, athenahealth launched an ongoing research project in 2016. Now in its second phase, the project surveyed nearly 1,400 practicing physicians in June 2018.


Other News
MEDICAL DEVICES

GeneQuantum Healthcare's Two Next Generation Bioconjugate Drugs, GQ1005 and GQ1007, Have Been Approved for Clinical Trials in Australia

GeneQuantum Healthcare | May 16, 2022

GeneQuantum Healthcare Co., Ltd. a global innovative biotechnology company dedicated to the development of bioconjugate drugs, announced that two of the company's bioconjugate drug candidates have won the approval for clinical trials in Australia, further enhancing GeneQuantum's pipelines in the clinical stage. They are GQ1005, an ADC with an excellent bystander killing effect, and GQ1007, a first-in-class antibody-immune-agonist-conjugateboth with global intellectual property rights. "The core technologies that we have focused on since the founding of GeneQuantum, bring the company into the harvest period for exciting next generation bioconjugate drugs. The EC approval of GQ1005 and GQ1007 in Australia is an important milestone for the company. More than once, GeneQuantum's enzymatic site-specific conjugation platform and the stable linker technology have demonstrated the advantages through several IND enabled drug candidates. GeneQuantum conjugation technologies are widely compatible to different molecular modalities with various Mechanism of Action. Committed to the core value of "breakthrough for humanity", GeneQuantum is dedicated to developing safe, effective, and affordable novel therapeutics for patients with cancer around the world." Dr. Gang Qin, founder, Chairman and Chief Executive Officer About GeneQuantum Healthcare Co., Ltd. GeneQuantum Healthcare Co., Ltd. is a global biotechnology company dedicated to the development of innovative biotherapeutics. The company is focused on the development of next generation bioconjugate therapeutics to address the unmet medical needs of patients globally. This press release contains statements relating to GeneQuantum's future business, future events or developments, and related statements may constitute forward-looking statements. Statements are based on current expectations and assumptions that are subject to risks and uncertainties, which may cause actual results to differ materially. Risks and uncertainties include, among other things, the uncertainties inherent in research and development, follow-up clinical data and analysis; factors that may cause any delay, transfer or change; regulatory authority decision whether and when to approve drug applications; factors that may lead actual results to seriously deviate from current expectations, etc. No forward-looking statement can be guaranteed. Except as required by applicable laws, GeneQuantum assumes no obligation to update or revise any forward-looking information or statements.

Read More

FUTURE OF HEALTHCARE

GTCR Announces Partnership with Kelly McCrann to Form Avryo Healthcare

GTCR | April 22, 2022

GTCR, a leading private equity firm, announced that it has entered into a Leaders Strategy™ partnership with Kelly McCrann to form Avryo Health Services, LLC. Based in San Diego, CA, Avryo Healthcare will seek to acquire companies and assets in the multi-site healthcare services industry as part of a strategy to build a market-leading company, with a focus on utilizing new technologies and operating strategies to enhance patient access and experiences. GTCR, the firm that pioneered The Leaders Strategy™ - finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth - will invest in Avryo Healthcare from its Strategic Growth Fund, a private equity fund with $2.0 billion of limited partner capital commitments. Mr. McCrann is serving as Executive Chairman of Avryo Healthcare and will make a substantial investment alongside GTCR. Mr. McCrann has over 30 years of experience in the healthcare services industry. Prior to partnering with GTCR, Mr. McCrann most recently served as Chief Executive Officer of EyeCare Partners, the largest vertically-integrated medical vision services provider in the US. He became CEO of EyeCare Partners in 2016 and significantly grew the company via acquisition and organic growth into the largest business in the industry before completing a successful sale of the company in 2019. Prior to leading EyeCare Partners, Mr. McCrann spent more than 25 years in senior leadership roles across healthcare provider services and payor businesses, including within dental, behavioral health, ambulatory infusion and kidney dialysis. "We are excited to partner with Kelly to build a leading company in the healthcare services industry," said Sean Cunningham, Managing Director and Co-Head of Healthcare at GTCR. "Kelly has an exceptional track record in the multi-site healthcare services space with experience across specialties, including dental and behavioral health, and a history of driving organic, de novo and M&A growth. Kelly's background, industry expertise and strategic vision make him an ideal partner as GTCR commits to build a platform in this attractive industry." "I am thrilled to partner with GTCR to build Avryo Healthcare into a market-leading company in the multi-site healthcare services space. GTCR has deep domain expertise in healthcare, a substantial track record of creatively building platforms in this space, and a long history of backing experienced CEOs and Executive Chairs. With our partnership, Avryo Healthcare is well-positioned to create a compelling platform in healthcare provider services." Mr. McCrann "GTCR's formation of Avryo Healthcare with Kelly is another excellent example of The Leaders Strategy™ and builds on our history of successful investments in multi-site healthcare services and the broader healthcare industry," added John Kos, Managing Director at GTCR. "We are excited to create this multi-site healthcare services platform behind Kelly and are actively looking for companies and assets in the sector, including founder-led and sponsor-backed companies." About GTCR Founded in 1980, GTCR is a leading private equity firm focused on investing in growth companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications industries. The Chicago-based firm pioneered The Leaders Strategy™ - finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through transformational acquisitions and organic growth. Since its inception, GTCR has invested more than $20 billion in over 250 companies. For more information, please visit www.gtcr.com. Follow us on LinkedIn. About Avryo Healthcare Avryo Healthcare was formed in April 2022 as a partnership between Kelly McCrann and GTCR. Avryo Healthcare's mission is to build a leading company in the multi-site healthcare provider services industry with a focus on building a company that utilizes new technologies and operating strategies to enhance patient access and experiences. For more information about Avryo Healthcare, please contact (212) 835-7042.

Read More

FUTURE OF HEALTHCARE

SpinaFX Medical to Exhibit at Society of Interventional Radiology Annual Scientific Meeting

Spinafx medical inc | June 13, 2022

Minimally invasive image-guided therapy company, SpinaFX Medical Inc. announced it will exhibit at the Society of Interventional Radiology (SIR) 2022 Annual Scientific Meeting inBoston, MA,June 11-16, at booth 414. Dr. Alexis Kelekis, medical advisor to SpinaFX, will present the results of a research study on which he was the lead author, recently published inThe Spine Journal, on the effectiveness of intradiscal oxygen-ozone treatment compared to microdiscectomy for contained lumbar disc herniation with radiculopathy. This study has been recognized by SIR as one of the 2022Abstracts of the Year. "We are excited to meet with some of the world's leading interventional radiologists to discuss innovations in minimally invasive, image-guided care and share our recent progress and momentum at SpinaFX. We look forward to Dr. Kelekis' presentation and celebrate the study's findings, which have the potential to benefit both patients and providers by addressing a significant gap in the continuum of care for the millions suffering from back pain." Jeff Cambra, SpinaFX CEO "I am thrilled that Dr. Kelekis will share the findings of our skilled research team at SIR's Annual Scientific Meeting," said Dr.Kieran Murphy, SpinaFX Chief Medical Officer and co-author of the recognized study. "The technology used in this randomized control trial holds great promise for patients struggling with contained herniated lumbar disc pain and it is an honor to have this research recognized by such a prestigious and well-respected organization." Dr. Alexis Kelekis willpresentthe results of his study onWednesday, June 15, at10:40 a.m.during Closing Plenary. As an exhibitor during the meeting onJune 11-16, SpinaFX will offer attendees the opportunity to discuss the study results and their implications with Drs. Kelekis and Murphy, learn more about SpinaFX and its goal to help develop minimally invasive, image-guided treatment options, and provide input on developing technology with the potential to redefine the treatment of contained herniated discs. Visit SIR'swebsiteto learn more about the Annual Scientific Meeting. About SpinaFX Headquartered inOntario, Canada, SpinaFX is a treatment solution and technology company bringing innovative, minimally invasive image-guided treatments to patients with back pain due to contained herniated discs.

Read More

HEALTH TECHNOLOGY

NUTEX HEALTH ANNOUNCES TWO NEW FULLY FUNCTIONAL MICRO HOSPITALS

Nutex Health, Inc. | May 17, 2022

Nutex Health Inc. a physician-led, technology-enabled healthcare services company comprised of a hospital division with 21 facilities in 8 states and a primary care-centric, risk-bearing population health management division, announced two new fully operational micro hospitals. The first hospital, New Braunfels ER & Hospital, is in New Braunfels, Texas, located about 30 miles northeast of San Antonio. The state-of-the-art facility is open 24/7, 365 days a year, and includes an emergency room with 9 private exam rooms staffed with board-certified physicians and 4 private inpatient beds. The hospital provides both adult and pediatric care, and has the most advanced imaging and laboratory equipment, including CT, X-Ray and ultrasound with rapid radiological reports. The second hospital, East Valley ER & Hospital, is in Gilbert, Arizona, located about 21 miles southeast of Phoenix. The state-of-the-art hospital is open 24/7, 365 days a year, and includes an emergency room with 14 private exam rooms and 14 private inpatient beds. The hospital provides both adult and pediatric care, and has the most advanced imaging and laboratory equipment, including MRI, CT, X-Ray and ultrasound. Nutex currently anticipates opening 3 more facilities in 2022, with another 17 facilities either under construction or in advanced planning stages and anticipated to open in 2023 and 2024. There can be no assurance that these additional facilities will open in the anticipated timing or that they will open at all. Nutex micro hospitals focus on ensuring that patients receive a premium patient experience. Our hospitals feature short ER wait times averaging 15 minutes from entering the door to seeing a physician, high-quality care, lower nursing- and physician-to-patient staffing ratios and faster discharge times. Physicians, nurses and other employees are incentivized to provide quality, compassionate care to their patients. Nutex micro hospitals consistently have better outcomes and high patient satisfaction scores, with well over 1000 five-star Google reviews. "We are excited to continue to expand Nutex's network of micro hospitals across the country. Both New Braunfels and Gilbert are vibrant and rapidly growing suburbs of major metropolitan areas. Our goal is to provide high-quality acute medical care to the populations of these communities." Tom Vo, M.D., MBA, Chairman and Chief Executive Officer of Nutex Health "Entering the medical field, my goal was always to try to revolutionize the way healthcare is delivered to our patients. Our unique model allows physicians and nurses to retake control of patient care," stated Trey Allen, M.D., Medical Director at New Braunfels ER & Hospital. "We are committed to working with the community to make sure they can receive the healthcare they deserve." "As physicians, we saw how healthcare was being delivered, and we felt we could do better. We felt the humanity and compassion were absent from many medical interactions. We value and respect our patients, and treat them as family," stated Daniel Stites, M.D., Medical Director at East Valley ER & Hospital. About Nutex Health Inc. Headquartered in Houston, Texas and founded in 2011, Nutex Health Inc. is a physician-led, technology-enabled healthcare services company with approximately 1500 employees nationwide and is partnered with over 800 physicians. The Company has two divisions a Hospital division and a Population Health Management division. The hospital division owns and operates 21 facilities in eight different states. The division implements and operates different innovative health care models, including micro hospitals, specialty hospitals and hospital outpatient departments. The Population Health Management division owns and operates provider networks such as Independent Physician Associations (IPAs). Through our Management Services Organizations, we provide management, administrative and other support services to our affiliated hospitals and physician groups. Our cloud-based proprietary technology platform aggregates clinical and claims data across multiple settings, information systems and sources to create a holistic view of patients and providers, allowing us to deliver greater quality care more efficiently. Safe Harbor Certain statements and information included in this press release constitute "forward-looking statements" within the meaning of the Federal Private Securities Litigation Act of 1995. When used in this press release, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include the ability to realize the anticipated benefits of the transaction, significant transaction costs and unknown liabilities and litigation and regulatory risks related to the transaction. In addition, forward-looking statements are subject to additional uncertainties and risks facing the Company, including but not limited to, economic conditions, dependence on management, dilution to stockholders, lack of capital, changes in laws or regulations, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this press release.

Read More

Spotlight

What matters most when building and sustaining a healthcare organization? What are the precise levers to pull to promote physician well-being, financial success, and better outcomes at lower cost? To answer these questions, athenahealth launched an ongoing research project in 2016. Now in its second phase, the project surveyed nearly 1,400 practicing physicians in June 2018.

Resources